Tenax Therapeutics (TENX) Competitors $7.46 -0.31 (-3.99%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$7.44 -0.02 (-0.27%) As of 10/10/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. HURA, OVID, ATOS, BMEA, TVGN, ZYBT, KLRS, IKT, VIRI, and CLYMShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include TuHURA Biosciences (HURA), Ovid Therapeutics (OVID), Atossa Genetics (ATOS), Biomea Fusion (BMEA), Tevogen Bio (TVGN), Zhengye Biotechnology (ZYBT), Kalaris Therapeutics (KLRS), Inhibikase Therapeutics (IKT), Virios Therapeutics (VIRI), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors TuHURA Biosciences Ovid Therapeutics Atossa Genetics Biomea Fusion Tevogen Bio Zhengye Biotechnology Kalaris Therapeutics Inhibikase Therapeutics Virios Therapeutics Climb Bio TuHURA Biosciences (NASDAQ:HURA) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk. Is HURA or TENX more profitable? Tenax Therapeutics' return on equity of -31.34% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A -248.79% -150.83% Tenax Therapeutics N/A -31.34%-30.39% Do insiders and institutionals believe in HURA or TENX? 0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, HURA or TENX? TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Which has preferable valuation and earnings, HURA or TENX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$21.68MN/AN/ATenax TherapeuticsN/AN/A-$17.60M-$0.92-8.11 Does the media refer more to HURA or TENX? In the previous week, TuHURA Biosciences had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for TuHURA Biosciences and 2 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.89 beat TuHURA Biosciences' score of 0.78 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate HURA or TENX? TuHURA Biosciences currently has a consensus price target of $12.67, indicating a potential upside of 429.99%. Tenax Therapeutics has a consensus price target of $18.00, indicating a potential upside of 141.29%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummaryTenax Therapeutics beats TuHURA Biosciences on 8 of the 12 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.45M$3.38B$6.11B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-8.1122.1185.5826.57Price / SalesN/A461.00613.00132.62Price / CashN/A47.2238.5062.09Price / Book0.2810.2112.756.53Net Income-$17.60M-$52.40M$3.31B$276.43M7 Day Performance-0.53%0.86%0.81%-0.86%1 Month Performance21.50%10.39%6.22%3.58%1 Year Performance119.41%27.24%80.35%37.94% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics2.9313 of 5 stars$7.46-4.0%$18.00+141.3%+116.2%$35.45MN/A-8.119News CoveragePositive NewsHURATuHURA Biosciences1.4951 of 5 stars$2.49-4.2%$12.67+408.7%N/A$132.87MN/A0.00N/ANews CoverageAnalyst ForecastOVIDOvid Therapeutics4.5234 of 5 stars$1.79-2.7%$3.10+73.2%+53.2%$130.84M$6.65M-3.3860News CoverageAnalyst ForecastATOSAtossa Genetics2.5809 of 5 stars$1.00-1.0%$6.25+525.0%-22.3%$130.46MN/A-4.358News CoverageAnalyst ForecastBMEABiomea Fusion3.2715 of 5 stars$2.67+24.2%$9.50+255.8%-84.4%$127.94MN/A-0.8850Analyst ForecastOptions VolumeHigh Trading VolumeTVGNTevogen Bio2.6103 of 5 stars$0.65-3.7%$10.00+1,441.3%+123.3%$127.62MN/A-3.413Analyst ForecastZYBTZhengye BiotechnologyN/A$2.88+7.5%N/AN/A$126.41M$25.53M0.00278News CoverageGap UpKLRSKalaris Therapeutics1.3324 of 5 stars$8.03+20.9%$3.00-62.6%N/A$124.18MN/A0.00110News CoverageAnalyst ForecastHigh Trading VolumeIKTInhibikase Therapeutics0.0719 of 5 stars$1.62-2.4%N/AN/A$123.70M$260K0.006News CoverageAnalyst ForecastGap DownVIRIVirios TherapeuticsN/A$6.41-0.2%$5.00-22.0%+79.5%$123.44MN/A-23.745Gap DownCLYMClimb Bio3.982 of 5 stars$1.81-8.6%$9.25+411.0%N/A$122.65MN/A-2.599Analyst ForecastShort Interest ↓ Related Companies and Tools Related Companies TuHURA Biosciences Alternatives Ovid Therapeutics Alternatives Atossa Genetics Alternatives Biomea Fusion Alternatives Tevogen Bio Alternatives Zhengye Biotechnology Alternatives Kalaris Therapeutics Alternatives Inhibikase Therapeutics Alternatives Virios Therapeutics Alternatives Climb Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
